What is SmartLabs?
Founded in 2015 and headquartered in Boston, Massachusetts, SmartLabs addresses the administrative and logistical challenges faced by companies in the life sciences sector. The company offers comprehensive solutions, including in-house design, architecture, construction management, and full-service facilities management, alongside a suite of shared amenities. This integrated approach aims to streamline the development and operational processes for research-intensive organizations, enabling them to focus on innovation rather than infrastructure.
How much funding has SmartLabs raised?
SmartLabs has raised a total of $387.8M across 4 funding rounds:
Angel/Seed
$8.8M
Series A
$81M
Series B
$250M
Series C
$48M
Angel/Seed (2015): $8.8M, investors not publicly disclosed
Series A (2020): $81M, investors not publicly disclosed
Series B (2021): $250M supported by Breed’s Hill Capital, Onex Falcon, Conversion Venture Capital, ArrowMark Partners, and Winslow Capital Management
Series C (2024): $48M featuring Conversion Venture Capital, ArrowMark Partners, and Winslow Capital Management
Key Investors in SmartLabs
Conversion Venture Capital
Conversion Venture Capital is a private equity and venture capital firm that invests its own capital alongside management teams and entrepreneurs to build segment-leading businesses. They offer flexible, patient capital with a focus on value creation and alignment of interests, without the constraints of traditional fund structures.
ArrowMark Partners
ArrowMark Partners is an employee-owned asset manager with specialized expertise in alternative credit and growth equity asset classes. The firm primarily provides its services to investment companies.
Winslow Capital Management
Winslow Capital is a premier growth equity investment firm headquartered in Minneapolis, Minnesota, founded in 1992.
What's next for SmartLabs?
The recent major strategic investment signals a pivotal phase for SmartLabs, likely enabling further expansion of its service offerings and market reach. With a history of substantial capital injections, including a Series B round of $250B and a Series C round of $48B, the company is well-positioned to scale its operations. This infusion of capital is expected to fuel product development, enhance its facilities management capabilities, and potentially support geographic expansion, solidifying its role as a key enabler of pharmaceutical research and development.
See full SmartLabs company page
